Navigation

Skiplink Navigation

Main Features

Actelion shakes up its management

Europe’s largest biotech company, Actelion of Basel, is changing its management structure after coming under pressure from investors Elliott Advisors.

In a statement on Tuesday, Actelion said it had appointed Otto Schwarz, head of business strategy and operations at Actelion since 2008, as chief operating officer.

This would allow chief executive Jean-Paul Clozel to focus more on strategic matters, it added.

“Together we are committed to move Actelion to the next stage  - advancing value creation for all stakeholders by turning innovation into successful medicines that change patients’ lives,” Clozel said.

“We will also continue to evaluate in-licensing and acquisitions and act decisively when we identify value-adding opportunities.”

Elliott had urged the Swiss biotech group to consider seeking a buyer after a string of product setbacks and had also accused Actelion of pursuing a high-risk strategy that had eroded shareholder value.

swissinfo.ch and agencies


Links

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletter and get the top stories delivered to your inbox.

×